|
|
|
| Effects of Beraprost Sodium on Scr BUN FIB D-D TNF-alpha, hs-CRP in Elderly Patients with Glomerulosclerosis of T2DM |
| LI Hongwei, WANG Zhiqi, ZHANG Ju |
| Liaoyang Central Hospital, Liaoyang, Liaoning LiaoYang 111000, China |
|
|
|
|
Abstract Objective: To investigate the effects of beraprost sodium on serum inflammatory factors, coagulation function and renal function in elderly patients with type 2 diabetes mellitus (T2DM) with glomerulosclerosis. Methods: 78 elderly patients with T2DM glomerulosclerosis admitted to our hospital from January 2016 to January 2019 were randomly divided into control group (treated with benazepril) and research group (treated with benazepril and beraprost sodium), 39 cases in each group by convenient sampling. The levels of serum inflammatory factor hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), coagulation function index D-dimer (D-D), fibrinogen (Fib) and renal function index blood urea nitrogen (BUN) and serum creatinine (SCr) were compared between the two groups before and after treatment. Results: Compared with before treatment, the contents of hs-CRP and TNF-α in the two groups decreased significantly 2 months after treatment (P<0.05); Compared with the control group, the contents of hs-CRP and TNF-α in the study group decreased significantly 2 months after treatment (P<0.05). The concentration of D-D and Fib in the control group did not change significantly after 2 months of treatment compared with that before treatment (P>0.05); The concentration of D-D and Fib in the study group decreased significantly after 2 months of treatment compared with that before treatment (P<0.05), and decreased significantly after treatment compared with that in the control group (P<0.05). The levels of BUN and SCr in the two groups were significantly lower than those before treatment, and the levels of BUN and SCr in the study group were significantly lower than those in the control group after treatment (P<0.05). Conclusion: Beraprost sodium therapy can effectively improve the coagulation function and renal function of elderly patients with glomerulosclerosis of type 2 diabetes mellitus on the basis of routine treatment, and regulate the level of inflammatory factors in vivo. It has significant therapeutic effect, so it is worthy of clinical application.
|
|
|
|
|
|
[1] Moriya T, Matsubara M, Kishihara E, et al. Type 2 diabetic patients with diabetic retinopathy and concomitant microalbuminuria showed typical diabetic glomerulosclerosis and progressive renal dysfunction[J].Diabetes Complications,2016,30(6):1111~1116.
[2] 李远,齐香梅,陈皇珍,等.全国名老中医对糖尿病肾病辨证与用药规律的数据分析[J].医学研究与教育,2016,33(5):13~20.
[3] 苟燕.前列地尔联合丹红对早期糖尿病肾病患者肾功能及血清炎症因子水平的影响[J].河北医学,2016,22(12):1948~1951.
[4] 乐宇娜.阿托伐他汀联合贝那普利对IgA肾病患者蛋白尿的影响[J].中国基层医药,2018,25(10):1307~1310.
[5] 黄静,常保超,刘磊,等.糖尿病肾病与炎性细胞因子的研究现状[J].蚌埠医学院学报,2016,41(10):1396~1399.
[6] Kim M, Kim JU, Kim SM, et al. Effectiveness of beraprost sodium in maintaining vascular access patency in patients on hemodialysis[J].Int Urol Nephrol,2017,49(7):1287~1295.
[7] 郑乐群,卢翔,张特,等.黄葵胶囊联合贝前列腺素钠和雷公藤多苷对早期糖尿病肾病的血流变和炎症因子的影响[J].中国慢性病预防与控制,2018,26(8):607~610.
[8] Li S, Wang Y, Chen L, et al. Beraprost sodium mitigates renal interstitial fibrosis through repairing renal microvessels[J].Mol Med (Berl),2019,97(6): 777~791.
[9] Zhou Y, Du L, Tu B, et al. Comparing the vascular thromboembolic events following arteriovenous fistula in Chinese population with end-stage renal diseases receiving Clopidogrel versus Beraprost sodium therapy: a retrospective cohort study[J].BMC Nephrol,2018,19(1):376.
[10] Shimamura M, Miyakawa J, Doi M, et al. The pharmacokinetics of beraprost sodium following single oral administration to subjects with impaired kidney function[J].Clin Pharmacol,2017,57(4):524~535. |
|
|
|
2020, Vol. 26 
